questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines membranaires
Glycoprotéines membranaires
Syndécanes
Syndécane-3
Syndécane-3 : Questions médicales fréquentes
Termes MeSH sélectionnés :
Multicenter Studies as Topic
Diagnostic
5
Syndécane-3
Tests génétiques
Biopsie
Immunohistochimie
Dosage sanguin
Syndécane-3
Marqueurs tumoraux
Cytokines
Symptômes
5
Dysfonction
Anomalies tissulaires
Cancer
Maladies inflammatoires
Anomalies cutanées
Syndécane-3
Prévention
5
Prévention
Mode de vie sain
Facteurs de risque
Inflammation chronique
Traitements
5
Thérapies ciblées
Anticorps monoclonaux
Effets secondaires
Réactions immunitaires
Traitements expérimentaux
Évaluation
Suivi
Réponse au traitement
Complications
5
Complications
Métastases tumorales
Complications cardiovasculaires
Syndécane-3
Complications neurologiques
Recherche
Gestion
Approche multidisciplinaire
Réversibilité
Traitement approprié
Facteurs de risque
5
Facteurs de risque
Antécédents familiaux
Obésité
Dysfonctionnements
Facteurs environnementaux
Polluants
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Syndécane-3 : Questions médicales les plus fréquentes",
"headline": "Syndécane-3 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Syndécane-3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-30",
"dateModified": "2025-04-25",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Syndécane-3"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Syndécanes",
"url": "https://questionsmedicales.fr/mesh/D053667",
"about": {
"@type": "MedicalCondition",
"name": "Syndécanes",
"code": {
"@type": "MedicalCode",
"code": "D053667",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.543.550.847"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Syndécane-3",
"alternateName": "Syndecan-3",
"code": {
"@type": "MedicalCode",
"code": "D053670",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Addolorata Pisconti",
"url": "https://questionsmedicales.fr/author/Addolorata%20Pisconti",
"affiliation": {
"@type": "Organization",
"name": "Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK."
}
},
{
"@type": "Person",
"name": "Martin Götte",
"url": "https://questionsmedicales.fr/author/Martin%20G%C3%B6tte",
"affiliation": {
"@type": "Organization",
"name": "Department of Gynecology and Obstetrics, Münster University Hospital, Albert-Schweitzer-Campus 1, D11, 48149 Muenster, Germany."
}
},
{
"@type": "Person",
"name": "Ilona Kovalszky",
"url": "https://questionsmedicales.fr/author/Ilona%20Kovalszky",
"affiliation": {
"@type": "Organization",
"name": "Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary."
}
},
{
"@type": "Person",
"name": "Samantha Arokiasamy",
"url": "https://questionsmedicales.fr/author/Samantha%20Arokiasamy",
"affiliation": {
"@type": "Organization",
"name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom."
}
},
{
"@type": "Person",
"name": "James R Whiteford",
"url": "https://questionsmedicales.fr/author/James%20R%20Whiteford",
"affiliation": {
"@type": "Organization",
"name": "Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Topical sirolimus solution for lingual microcystic lymphatic malformations in children and adults (TOPGUN): study protocol for a multicenter, randomized, assessor-blinded, controlled, stepped-wedge clinical trial.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35804404",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s13063-022-06365-y"
}
},
{
"@type": "ScholarlyArticle",
"name": "Access to rehabilitation after stroke in Brazil (AReA study): multicenter study protocol.",
"datePublished": "2022-12-19",
"url": "https://questionsmedicales.fr/article/36535291",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1055/s-0042-1758558"
}
},
{
"@type": "ScholarlyArticle",
"name": "Surgical Outcomes of Primary Dermatofibrosarcoma Protuberans: A Retrospective, Multicenter Study.",
"datePublished": "2022-08-06",
"url": "https://questionsmedicales.fr/article/35933538",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12351-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study Protocol of a Prospective Multicenter Observational Study Evaluating Acute Lower Limb Ischemia.",
"datePublished": "2022-11-05",
"url": "https://questionsmedicales.fr/article/36347128",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jss.2022.09.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Study protocol of Branch Atheromatous Disease-related stroke (BAD-study): a multicenter prospective cohort study.",
"datePublished": "2022-12-09",
"url": "https://questionsmedicales.fr/article/36494618",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s12883-022-02976-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008565"
},
{
"@type": "ListItem",
"position": 5,
"name": "Glycoprotéines membranaires",
"item": "https://questionsmedicales.fr/mesh/D008562"
},
{
"@type": "ListItem",
"position": 6,
"name": "Syndécanes",
"item": "https://questionsmedicales.fr/mesh/D053667"
},
{
"@type": "ListItem",
"position": 7,
"name": "Syndécane-3",
"item": "https://questionsmedicales.fr/mesh/D053670"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Syndécane-3 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Syndécane-3",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-08",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Syndécane-3",
"description": "Comment diagnostiquer une anomalie du syndécane-3 ?\nQuels examens sont utilisés pour évaluer le syndécane-3 ?\nLe dosage sanguin peut-il aider au diagnostic ?\nQuels marqueurs sont associés au syndécane-3 ?\nLe diagnostic est-il difficile à établir ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Syndécane-3",
"description": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?\nLe syndécane-3 est-il lié à des maladies spécifiques ?\nPeut-on observer des symptômes cutanés ?\nY a-t-il des symptômes systémiques associés ?\nLes symptômes varient-ils d'un patient à l'autre ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Syndécane-3",
"description": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?\nY a-t-il des facteurs de risque connus ?\nDes dépistages réguliers sont-ils recommandés ?\nL'alimentation influence-t-elle le syndécane-3 ?\nLe stress a-t-il un impact sur le syndécane-3 ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Syndécane-3",
"description": "Quels traitements ciblent le syndécane-3 ?\nLe traitement est-il efficace ?\nY a-t-il des effets secondaires des traitements ?\nDes traitements expérimentaux existent-ils ?\nLe suivi est-il nécessaire après traitement ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Syndécane-3",
"description": "Quelles complications peuvent survenir avec le syndécane-3 ?\nLe syndécane-3 est-il lié à des complications cardiovasculaires ?\nDes complications neurologiques sont-elles possibles ?\nComment gérer les complications liées au syndécane-3 ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Syndécane-3",
"description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il les risques ?\nLes infections jouent-elles un rôle ?\nY a-t-il un lien avec l'obésité ?\nLes facteurs environnementaux sont-ils significatifs ?",
"url": "https://questionsmedicales.fr/mesh/D053670?mesh_terms=Multicenter+Studies+as+Topic#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie du syndécane-3 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests génétiques et des analyses de tissus pour évaluer l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels examens sont utilisés pour évaluer le syndécane-3 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies et des analyses immunohistochimiques peuvent être réalisées pour évaluer le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le dosage sanguin peut-il aider au diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Actuellement, il n'existe pas de dosage sanguin standardisé pour le syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels marqueurs sont associés au syndécane-3 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs tumoraux et des cytokines peuvent être associés à l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Le diagnostic est-il difficile à établir ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diagnostic peut être complexe en raison de la variabilité de l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Quels symptômes sont liés à une dysfonction du syndécane-3 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des troubles de l'adhésion cellulaire et des anomalies tissulaires."
}
},
{
"@type": "Question",
"name": "Le syndécane-3 est-il lié à des maladies spécifiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est impliqué dans des maladies comme le cancer et les maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes cutanés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent survenir en raison de l'implication du syndécane-3 dans la peau."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes systémiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes systémiques comme la fatigue et la douleur peuvent être observés dans certains cas."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils d'un patient à l'autre ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier considérablement selon l'individu et la pathologie associée."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les dysfonctionnements du syndécane-3 ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un mode de vie sain peut réduire certains risques associés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des facteurs comme l'inflammation chronique et des prédispositions génétiques sont identifiés."
}
},
{
"@type": "Question",
"name": "Des dépistages réguliers sont-ils recommandés ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dépistages peuvent être recommandés pour les personnes à risque élevé de maladies associées."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le syndécane-3 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut influencer positivement l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le syndécane-3 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress peut affecter l'expression du syndécane-3 et contribuer à des maladies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent le syndécane-3 ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des anticorps monoclonaux peuvent être utilisés pour cibler le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le traitement est-il efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité du traitement dépend de la pathologie et de l'expression du syndécane-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des traitements ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent entraîner des effets secondaires comme des réactions immunitaires."
}
},
{
"@type": "Question",
"name": "Des traitements expérimentaux existent-ils ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des traitements expérimentaux sont en cours d'évaluation pour cibler le syndécane-3."
}
},
{
"@type": "Question",
"name": "Le suivi est-il nécessaire après traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier est essentiel pour évaluer la réponse au traitement et ajuster si nécessaire."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec le syndécane-3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des métastases tumorales et des troubles immunitaires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Le syndécane-3 est-il lié à des complications cardiovasculaires ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des études suggèrent un lien entre le syndécane-3 et des complications cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Des complications neurologiques sont-elles possibles ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines recherches indiquent que des complications neurologiques peuvent être associées."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications liées au syndécane-3 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "La gestion des complications nécessite une approche multidisciplinaire et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié, d'autres non."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et les maladies inflammatoires."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie sédentaire et une mauvaise alimentation augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les infections jouent-elles un rôle ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections chroniques peuvent augmenter le risque de dysfonction du syndécane-3."
}
},
{
"@type": "Question",
"name": "Y a-t-il un lien avec l'obésité ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est un facteur de risque reconnu pour des dysfonctionnements associés au syndécane-3."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux sont-ils significatifs ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des polluants environnementaux peut influencer l'expression du syndécane-3."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 25/04/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Biochemistry, IIB, University of Liverpool, Liverpool, UK.
Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA.
Publications dans "Syndécane-3" :
4 publications dans cette catégorie
Affiliations :
Department of Gynecology and Obstetrics, Münster University Hospital, Albert-Schweitzer-Campus 1, D11, 48149 Muenster, Germany.
Publications dans "Syndécane-3" :
4 publications dans cette catégorie
Affiliations :
Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Pharmacoidea Ltd., H-6726 Szeged, Hungary.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Pharmacoidea Ltd., H-6726 Szeged, Hungary.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
K.G. Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
ICBMS, UMR 5246 CNRS - University Lyon 1, Univ Lyon, Villeurbanne, France.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Biotech Research & Innovation Centre, University of Copenhagen, 2200 Copenhagen, Denmark.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Department of Gynecology and Obstetrics, Münster University Hospital, Munster, Germany.
Disciplina de Biologia Molecular, Departamento de Bioquímica, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Publications dans "Syndécane-3" :
3 publications dans cette catégorie
Affiliations :
Disciplina de Biologia Molecular, Departamento de Bioquímica, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Departamento de Ciências Biológicas, Instituto de Ciências Ambientais, Químicas e Farmacêuticas, Universidade Federal de São Paulo, Sao Paulo, Brazil.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
Barts and the London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
Albert Szent-Györgyi Clinical Center, Department of Medicine, Faculty of Medicine, University of Szeged, H-6720 Szeged, Hungary.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Cell Biology, Stony Brook University, Stony Brook, NY, USA.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
Bjørknes College, Oslo, Norway.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
Institute for Experimental Medical Research, Oslo University Hospital and University of Oslo, Oslo, Norway.
K.G. Jebsen Center for Cardiac Research, University of Oslo, Oslo, Norway.
Publications dans "Syndécane-3" :
2 publications dans cette catégorie
Affiliations :
ICBMS, UMR 5246 CNRS - University Lyon 1, Univ Lyon, Villeurbanne, France.
Publications dans "Syndécane-3" :
Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations presenting as clusters of cysts filled with lymph fluid or blood. Even small well-limited lesions can be ...
This is a randomized, multicentric study using an individually randomized stepped-wedge design over 24 weeks to evaluate topical application of a 1 mg/mL sirolimus solution once daily, on LMLM, versus...
Given the disappointing state of current treatment options in LMLMs, topical sirolimus could become firstline therapy in treating LMLMs if its efficacy and safety were to be demonstrated....
ClinicalTrials.gov NCT04128722 . Registered on 24 September 2019. EudraCT: EUCTR2019-001530-33-FR Sponsor (University Hospital Center of Tours - CHRU Tours): DR190041-TOPGUN French regulatory authorit...
Most of the Brazilian population relies on public healthcare and stroke is a major cause of disability in this country of continental dimensions. There is limited information about access to rehabilit...
To provide comprehensive information about Access to Rehabilitation After discharge from public hospitals in Brazil (AReA study), up to 6 months after stroke....
The present study intends to collect information from 17 public health centers in 16 Brazilian cities in the 5 macroregions of the country. Each center will include 36 participants (...
The study is ongoing. Recruitment started on January 31...
The AReA study will fill a gap in knowledge about access to stroke rehabilitation in the public health system in different Brazilian regions....
Dermatofibrosarcoma protuberans (DFSP) is a locally aggressive tumor with a low rate of metastatic disease. Previous series have shown a superiority of Mohs micrographic surgery (MMS) compared with wi...
The purpose of the current study was to examine the outcome of surgical treatment of primary DFSP of the trunk and extremities....
We reviewed 236 patients (115 females, 121 males, mean age 41 ± 15 years) undergoing MMS (n = 81, 34%) or WLE (n = 155, 66%) to treat a primary DFSP. Mean tumor size and follow-up was 4 ± 2 cm and 7 y...
There was no difference (p > 0.05) in patient age, sex, tumor size, negative margin excision, or history of a previous inadvertent excision between patients who underwent WLE and those undergoing MMS....
There was no difference in oncologic outcome comparing MMS with WLE for DFSP outside the head and neck. The goal of treatment for DFSP is to achieve a negative margin, regardless of surgical treatment...
Acute lower limb ischemia (ALI) is a limb- and potentially life-threatening condition which requires urgent evaluation and treatment. Contemporary data on optimal therapy and prognosis of ALI are lack...
The proposed study is a prospective, international, multicenter, observational study on ALI (PROMOTE-ALI) (ClinicalTrials.gov - NCT05138679). Patients with ALI (Rutherford classification grade I -III)...
ALI remains a challenging condition and due to the heterogeneous etiology, clinical presentation and treatment strategies, a large multicenter study on this topic is needed to gain contemporary data o...
As a meaningful subtype of ischemic stroke in Asians, Branch atheromatous disease (BAD)-related stroke is associated with high early neurological deterioration (END) and disability, but is understudie...
BAD-study is a nationwide, multicenter, consecutive, prospective, observational cohort study enrolling patients aged 18-80 years with BAD-related stroke within 72 h after symptom onset. Initial clinic...
BAD-study can provide demographic, clinical, radiological, and prognostic characteristics of BAD-related stroke, and thereby potentially figure out the vascular mechanism of early neurological deterio...
Narrowband ultraviolet B (NB-UVB) phototherapy is commonly prescribed for patients with moderate-to-severe atopic eczema (AE). The efficacy of NB-UVB, however, has not yet properly been established, a...
A pragmatic, multicenter, PROBE trial will be performed with 1:1 randomization of 316 adult patients with moderate-to-severe AE who have inadequate disease control with topical therapy and who are eli...
The UPDATE trial aims to provide high-quality evidence regarding the (cost-)effectiveness and safety of NB-UVB phototherapy in moderate-to-severe AE patients. Challenges that are addressed in the prot...
ClinicalTrials.gov NCT05704205. Registered on December 8, 2022....
Epidemiological data on cerebral venous thrombosis in China are still lacking at present on the aspects of incidence, recurrence, risk factors, and so on. Herein, we aimed to fill the gap, based on th...
Rectal cancer is a common cancer worldwide. Surgery for rectal cancer with low anterior resection often includes the formation of a temporary protective loop ileostomy. The temporary ostomy is later r...
The present multicenter, double-blinded, randomized, controlled study will compare standard suture closure of the abdominal wall in loop ileostomy reversal with retromuscular synthetic mesh at the sto...
This double-blinded randomized controlled superiority study will compare retromuscular synthetic mesh during the closure of loop ileostomy to standard care. If this study can show a lower frequency of...
ClinicalTrials.gov NCT03720262. Registered on October 25, 2018....
Multicenter contemporary data describing short-term outcomes after initial interventions of neonates with pulmonary atresia with intact ventricular septum (PA-IVS) are limited. This multicenter study ...
Neonates with PA-IVS who underwent surgical or catheter intervention between 2009 and 2019 in 19 centers were reviewed. Risk factors for MACE, defined as cardiopulmonary resuscitation, mechanical circ...
We reviewed 279 neonates: 79 (28%) underwent right ventricular decompression, 151 (54%) underwent systemic-to-pulmonary shunt or ductal stent placement only, 36 (13%) underwent right ventricular decom...
In a multicenter cohort, 1 in 5 neonates with PA-IVS experienced MACE after their initial intervention. Patients with 2 major coronary artery stenoses or lower weight at the time of the initial proced...
Cases of Toxoplasma reactivation or more severe primary infection have been reported in patients receiving immunosuppressive (IS) treatment for autoimmune diseases (AID). The purpose of this study was...
A multicenter descriptive study was conducted using data from the French National Reference Center for Toxoplasmosis (NRCT) that received DNA extracts or strains isolated from patients, associated wit...
61 cases were collected: 25 retrieved by the NRCT and by a call for observations and 36 from a literature review. Half of the cases were attributed to reactivation (50.9%), and most of cases (49.2%) w...
Although this remains a rare condition, clinicians should be aware for the management of patients and for the choice of IS treatment....